Ryan Sullivan

Nov 1, 2024 | jitc.bmj.com | JAMES GULLEY |Ryan Sullivan |Claire F. Friedman |P Sonpavde

AbstractBackground Invikafusp alfa, a dual T cell agonist, promotes the selective activation and expansion of Vβ6/Vβ10 TCR-expressing CD8+ and CD4+ effector memory T cells, which in nonclinical studies promote potent anti-tumor activity in anti-PD(L)1-resistant solid tumors.1 2Methods START001 is a first-in-human, multicenter Phase 1/2 study evaluating invikafusp as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich solid tumors (TMB-H, MSI-H/dMMR, or virally associated).

Aug 19, 2023 | mdpi.com | Meghan J. Mooradian |Ryan Sullivan

1. IntroductionCancer immunotherapy was transformed by the identification of key immune checkpoints and the subsequent clinical translation of immune checkpoint inhibitors (ICIs). The first of these, ipilimumab, blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and was approved to treat advanced melanoma in 2011.

Jul 21, 2023 | onclive.com | Ryan Sullivan

Ryan J. Sullivan, MD, associate professor of medicine, Harvard Medical School, associate director. the Melanoma Program, Massachusetts General Cancer, discusses the early reduction of circulating tumor DNA (ctDNA) in patients with metastatic uveal melanoma treated with tebentafusp-tebn (Kimmtrak) and shares how these reductions could correlate with longer overall survival (OS) in patients with a best response of stable disease.

Jun 26, 2023 | physiciansweekly.com | Meghan J. Mooradian |Ryan Sullivan

The development of highly effective BRAF-targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high-risk stage II and III settings.